Eris Lifesciences reappoints Sujesh Vasudevan as independent director
- Eris Lifesciences reappointed Sujesh Vasudevan as Independent Director for five years
- New term commences July 25, 2027, and ends July 24, 2032
- Board scheduled the 20th AGM for September 25, 2026
- Decisions approved during the August 31, 2026 board meeting

*this image is generated using AI for illustrative purposes only.
Eris Lifesciences has approved the re-appointment of Mr. Sujesh Vasudevan as an Independent Director for a five-year term. The Board also scheduled the company’s 20th Annual General Meeting for September 25, 2026.
The decisions were taken during a Board meeting held on August 31, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Board Approvals
Based on the recommendation of the Nomination & Remuneration Committee, the Board recommended Mr. Vasudevan’s re-appointment to shareholders. His new tenure is set to commence on July 25, 2027, and will run until July 24, 2032.
The Board also convened the 20th Annual General Meeting of members. The meeting is scheduled to take place on Friday, September 25, 2026.
Meeting Details
The Board of Directors meeting began at 10:30 am and concluded at 11:00 am. Milind Talegaonkar, Company Secretary & Compliance Officer, certified the disclosures.
Historical Stock Returns for Eris Lifesciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.80% | -1.80% | -6.22% | -3.98% | -27.24% | 0.0% |
How might Mr. Vasudevan's continued leadership as an Independent Director influence Eris Lifesciences' strategic direction in the generic and specialty pharmaceuticals sectors?
What specific governance or compliance initiatives are shareholders likely to prioritize for discussion at the 20th Annual General Meeting in September 2026?
Could the re-appointment signal stability in the boardroom that positively impacts investor confidence ahead of the company's upcoming financial reporting cycles?


































